PMS-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.
Brand(s)
Summary
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
Pharmascience |
PMS-FLUOXETINE 10mg |
DIN 02177579 |
Capsules |
FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 10mg |
644913, 643517, 648104, 646137, 653478, 648683, 648063, 648065, 647542, 641417, 641895, 646134, 644911, 643518, 643213, 645409, 642179, 644912, 642513, 655449, 649562, 648682, 651196, 653477, 648067, 647317, 645496, 646133, 645498, 646135 & 648066 |
Pharmascience |
PMS-FLUOXETINE 20mg |
DIN 02177587 |
Capsules |
FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 20mg |
644549, 645412, 642182 & 641413 |
Issue
The affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Pharmascience Inc. 100-6111 Royalmount Ave, Montreal, QC, Canada H4P 2T4
Get notified
Receive notifications for new and updated recalls and alerts by category.